Copyright
©The Author(s) 2021.
World J Clin Cases. Apr 26, 2021; 9(12): 2711-2720
Published online Apr 26, 2021. doi: 10.12998/wjcc.v9.i12.2711
Published online Apr 26, 2021. doi: 10.12998/wjcc.v9.i12.2711
Figure 2 Polycystic ovary syndrome may increase susceptibility to coronavirus disease 2019 via its associated comorbidities (non-alcoholic fatty liver disease, metabolic syndrome, obesity, insulin resistance and alterations in the gut microbiome); the gut-lung axis is apparently implicated.
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; IL-22: Interleukin 22, IL-6: Interleukin 6; PCOS: Polycystic ovary syndrome; NAFLD: Non-alcoholic fatty liver disease; COVID-19: Coronavirus disease 2019; MetSy: Metabolic syndrome.
- Citation: Ilias I, Goulas S, Zabuliene L. Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19. World J Clin Cases 2021; 9(12): 2711-2720
- URL: https://www.wjgnet.com/2307-8960/full/v9/i12/2711.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i12.2711